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ABSTRACT Indigenous populations experience high rates of otitis media (OM), with
increased chronicity and severity, compared to those experienced by their nonindig-
enous counterparts. Data on immune responses to otopathogenic bacteria in these
high-risk populations are lacking. Nontypeable Haemophilus influenzae (NTHi) is the
predominant otopathogen in Australia. No vaccines are currently licensed to target
NTHi; however, protein D (PD) from NTHi is included as a carrier protein in the 10-
valent pneumococcal polysaccharide conjugate vaccine (PHiD10-CV), and other
promising protein vaccine candidates exist, including outer membrane protein 4 (P4)
and protein 6 (P6). We measured the levels of serum and salivary IgA and IgG
against PD, P4, and P6 in Aboriginal and non-Aboriginal children with chronic OM
who were undergoing surgery and compared the levels with those in healthy non-
Aboriginal children (controls). We found that Aboriginal cases had lower serum IgG
titers to all NTHi proteins assessed, particularly PD. In contrast, serum IgA and sali-
vary IgA and IgG titers to each of these 3 proteins were equivalent to or higher than
those in both non-Aboriginal cases and healthy controls. While serum antibody lev-
els increased with age in healthy controls, no changes in titers were observed with
age in non-Aboriginal cases, and a trend toward decreasing titers with age was ob-
served in Aboriginal cases. This suggests that decreased serum IgG responses to
NTHi outer membrane proteins may contribute to the development of chronic and
severe OM in Australian Aboriginal children and other indigenous populations. These
data are important for understanding the potential benefits of PHiD10-CV implemen-
tation and the development of NTHi protein-based vaccines for indigenous popula-
tions.
KEYWORDS Australian Aboriginal, indigenous, antibody, nontypeable Haemophilus
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Australian Aboriginal children experience an excessive burden of otitis media (OM)and associated hearing loss, which causes difficulties in language acquisition and
learning and has long-term effects on their life course (1–3). While 10 to 20% of
nonindigenous children develop chronic or recurrent OM, the condition is almost
universal among Australian Aboriginal children by 12 months of age and persists to
school age (4–6). OM is also endemic in other indigenous populations, such as Native
American, Greenlandic and Alaskan Inuit, and Maori populations (7); however, the rates
of OM reported for Australian Aboriginal children are the highest in the world (8).
Received 16 December 2016 Returned for
modification 10 January 2017 Accepted 23
January 2017
Accepted manuscript posted online 1
February 2017
Citation Thornton RB, Kirkham L-AS,
Corscadden KJ, Wiertsema SP, Fuery A, Jones
BJ, Coates HL, Vijayasekaran S, Zhang G, Keil A,
Richmond PC. 2017. Australian Aboriginal
children with otitis media have reduced
antibody titers to specific nontypeable
Haemophilus influenzae vaccine antigens. Clin
Vaccine Immunol 24:e00556-16. https://
doi.org/10.1128/CVI.00556-16.
Editor Kathryn M. Edwards, Vanderbilt
University Medical Center
Copyright © 2017 Thornton et al. This is an
open-access article distributed under the terms
of the Creative Commons Attribution 4.0
International license.
Address correspondence to Ruth B. Thornton,
ruth.thornton@uwa.edu.au.
* Present address: Selma P. Wiertsema,
Immunology Group, Danone Nutricia, Utrecht,
The Netherlands; Angela Fuery, Virology and
Microbiology Group, Baylor College of
Medicine, Houston, Texas, USA.
CLINICAL IMMUNOLOGY
crossm
April 2017 Volume 24 Issue 4 e00556-16 cvi.asm.org 1Clinical and Vaccine Immunology
 on S
eptem









OM occurs much earlier in Australian Aboriginal children than in their non-
Aboriginal counterparts, often developing within weeks after birth (9). Disease onset at
this time is associated with very early and dense nasopharyngeal colonization with the
major otopathogens, i.e., nontypeable Haemophilus influenzae (NTHi), Streptococcus
pneumoniae, and Moraxella catarrhalis (10, 11). NTHi is now the predominant pathogen
isolated from the nasopharynx, middle ear effusion (MEE), and middle ear discharge of
Australian Aboriginal and non-Aboriginal children with OM (12, 13). Specific antibody
deficiencies may increase the susceptibility of children to both colonization and chronic
infection with these otopathogens. Previously, we and others demonstrated that
otitis-prone non-Aboriginal children under 3 years of age develop similar or higher
antibody responses to conserved bacterial protein antigens, compared with their
healthy, age-matched counterparts (14–19). We also recently demonstrated that Aus-
tralian Aboriginal children with OM produce similar antibody titers in response to
conserved proteins of S. pneumoniae (20). This finding is in contrast to other studies
that observed impaired antigen-specific immune responses to proteins from NTHi and
S. pneumoniae (21–25). Despite the almost universal nature of OM in Aboriginal
communities and the predominance of NTHi disease, no studies have been conducted
to assess specifically the naturally acquired NTHi-specific antibodies in Aboriginal
children. These data are important to determine which surface-exposed proteins are
immunogenic and/or appear to be protective, to help guide development of the best
vaccine candidates for a broadly protective NTHi vaccine for Australian Aboriginal
children.
Currently, a single vaccine containing an NTHi protein, i.e., protein D (PD), as a carrier
protein in a 10-valent pneumococcal polysaccharide conjugate vaccine (PHiD10-CV)
has been licensed. While licensure of PHiD10-CV was not for NTHi disease, in some trials
this vaccine showed the potential to decrease NTHi-associated OM (26, 27), including
in Australian Aboriginal children (26). Again, the data are conflicting, with several large
randomized controlled trials not being able to demonstrate PHiD10-CV protection
against acute OM (AOM) caused by NTHi (28–30). Interestingly, immunization with
PHiD10-CV does not appear to significantly reduce nasopharyngeal carriage of NTHi
(26–28, 31), suggesting that the effect of this vaccine is compartmental. This compart-
mental effect was also observed in animal models of disease, where reductions in NTHi
infection of the middle ear cavity did not correlate with decreases in nasopharyngeal
colonization (32). Data on naturally acquired anti-PD antibody titers in children with OM
are again conflicting; our study in younger, otitis-prone, Australian non-Aboriginal
children showed that they produced anti-PD antibody titers equivalent to those of
non-otitis-prone children (14), whereas a study with “stringently defined” otitis-prone
U.S. children observed deficiencies in anti-PD antibody titers (23). It has also been
suggested that the protection afforded by PHiD10-CV against OM may be due not to
induction of anti-PD antibodies but rather to the prevention of pneumococcal AOM
and the initial damage that it may cause, which enables progression to complex OM
(33). While the reduction of NTHi OM with PHiD10-CV immunization in some studies is
promising, recent studies have indicated that the PD gene (hpd) is missing in a
substantial subset of NTHi strains (34–36), which may enable vaccine evasion and
expansion of such lineages in the community (33). Multivalent vaccines that target
multiple strains of NTHi colonizing the nasopharynx and causing OM are required to
significantly reduce the burden of NTHi OM.
Outer membrane protein 4 (P4) and protein 6 (P6) are essential for NTHi adhesion,
colonization, and subsequent infection (37) and thus represent attractive vaccine
candidates for NTHi-related mucosal infections such as OM. These antigens are crucial
in the pathogenesis of NTHi and, in preclinical animal models (38–40), they elicit
protective antibody responses (38, 40–43) and enhance the mucosal clearance of NTHi
(39–42, 44). There are conflicting data regarding whether otitis-prone children have
impaired immunity to P4 and P6 (14, 23, 25). As both P4 and P6 are highly conserved
and promising candidates that may be included in a multiprotein vaccine, it is impor-
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tant to understand whether they are immunogenic and whether population differences
exist, particularly among those at greatest risk of OM.
The aim of this study was to determine the naturally acquired mucosal and systemic
antibody responses to the NTHi antigens PD, P4, and P6 in Australian Aboriginal and
non-Aboriginal children with OM, compared to healthy children without chronic dis-
ease. Such information is important for understanding the potential benefits of
PHiD10-CV implementation in indigenous populations and for developing future
protein-based NTHi vaccines.
RESULTS
Study population. A total of 183 children were recruited, including 36 healthy
children, who were all non-Aboriginal, and 70 Aboriginal and 77 non-Aboriginal
children undergoing surgery for OM. None of the healthy control children had any
significant history of respiratory disease (including OM), 74% of the non-Aboriginal cases
and 63% of the Aboriginal cases were undergoing surgery for ventilation tube insertion,
and 21% of the non-Aboriginal cases and 31% of the Aboriginal cases were undergoing
surgery for tympanoplasty (Table 1). The majority of non-Aboriginal cases were undergoing
surgery because of a diagnosis of OM with effusion (OME) (79%) and/or recurrent AOM
(rAOM) (47%), whereas 61% of the Aboriginal children had current diagnoses of OME and
34% chronic suppurative OM (CSOM) (Table 1). One non-Aboriginal case was also under-
going a mastoidectomy because of mastoiditis. One Aboriginal case and 2 non-Aboriginal
cases were concomitantly diagnosed with cholesteatomas.
Confounding factors associated with differences in antibody levels between Aborig-
inal cases, non-Aboriginal cases, and healthy controls were assessed. Age had the
greatest effect on salivary IgA antibody titers against P4, P6, and PD (P  0.05), while








No. 36 70 77 NA
Age (mean [range]) (yr) 8.3 (1.6–14.4) 6.7 (1.7–12.7) 5.0 (1.1–13.6) 0.01
Age group (no. [%])
1–3 yr 7 (19) 13 (19) 28 (36) 0.01
4–6 yr 7 (19) 24 (34) 29 (38)
7–11 yr 13 (36) 28 (40) 18 (23)
11 yr 9 (25) 5 (7) 2 (3)
Male (no. [%]) 13 (36) 39 (56) 39 (51) 0.20
Had attended day care (no. [%]) 23 (64) 28 (40) 43 (56) 0.29
History of CSOM (no. [%]) 0 (0) 26 (37) 8 (10) 0.01
Current surgery (no. [%])
VTIa NAe 44 (63) 57 (74) 0.20
Myringotomy NA 4 (6) 4 (5) 0.35
Tympanoplastyb NA 22 (31) 16 (21) 0.10
Adenoidectomy NA 1 (1) 10 (13) 0.02
Principal diagnosis (no. [%])
OME NA 43 (61) 61 (79) 0.05
rAOM NA 21 (30) 36 (47) 0.02
CSOM NA 24 (34) 6 (8) 0.01
Immunizations up to date (no. [%]) 36 (100) 52 (74) 69 (90) 0.15
Had received Prevenar (%)c 33 14 19 0.09
Receiving antibiotics at enrollment (%)d 0 3 12 0.02
aVTI, ventilation tube insertion.
bSeven tympanoplasties were performed due to failure of tympanic membrane healing after ventilation tube
insertion.
cHealthy controls, n  36; Aboriginal cases, n  56; non-Aboriginal cases, n  73.
dHealthy controls, n  36; Aboriginal cases, n  65; non-Aboriginal cases, n  75.
eNA, not applicable.
NTHi Antibodies in Australian Aboriginal Children Clinical and Vaccine Immunology
April 2017 Volume 24 Issue 4 e00556-16 cvi.asm.org 3
 on S
eptem









having no effect on serum IgA or IgG or salivary IgG titers. All antibody titers reported
were adjusted for age. Previous day care attendance and gender were demonstrated to
have no significant effects on antibody titers to any of the antigens tested (data not
shown).
Middle ear effusion cultures. A total of 106 MEE specimens from 74 children were
cultured; of those, 23 MEE specimens from 19 children were culture positive (22% of
MEE specimens from 26% of the children). Five MEE specimens from 5 children (3
Aboriginal and 2 non-Aboriginal) were culture positive for H. influenzae, and MEE
specimens from the left and right ears of 1 non-Aboriginal child were positive for S.
pneumoniae. Five MEE specimens from 3 children (2 Aboriginal and 1 non-Aboriginal)
were positive for M. catarrhalis, while 7 MEE specimens from 6 children (4 Aboriginal
and 2 non-Aboriginal) were positive for Pseudomonas aeruginosa. Finally, 4 MEE spec-
imens from 4 children (3 Aboriginal and 1 non-Aboriginal) were positive for Staphylo-
coccus aureus.
Systemic production of IgG in response to all 3 NTHi proteins was significantly
lower in Aboriginal children with OM than in non-Aboriginal children with OM
and healthy controls. Aboriginal children with OM had significantly lower serum IgG
titers to P4, P6, and PD than did non-Aboriginal children with OM or healthy controls
(P  0.004) (Fig. 1A). Anti-PD serum IgG titers were significantly lower in both Aborig-
inal and non-Aboriginal children with OM than in healthy controls (P  0.003) and were
also lower in Aboriginal children with OM than in non-Aboriginal children with OM (P 
0.002) (Fig. 1A). Anti-P4 serum IgG titers were significantly lower in Aboriginal children
with OM than in non-Aboriginal children with OM (P  0.0001) and healthy controls
(P  0.0001). Anti-P6 serum IgG titers were significantly lower in Aboriginal children
FIG 1 Comparison of serum IgG (A), serum IgA (B), salivary IgG (C), and salivary IgA (D) antibody titers between healthy non-Aboriginal children, Aboriginal
children with otitis media, and non-Aboriginal children with otitis media. Levels of serum IgG and IgA antibodies and salivary IgG and IgA antibodies against
NTHi proteins are presented for each individual child, with the horizontal bars depicting the medians. Statistical analyses were conducted on the geometric
means of logarithmically transformed data, correcting for age. e, healthy controls; Œ, non-Aboriginal children with OM; , Aboriginal children with OM. P4,
outer membrane protein 4; P6, outer membrane protein 6; PD, protein D. *, P  0.05; **, P  0.01; ***, P  0.001.
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with OM than in healthy controls (P  0.042). Conversely anti-P6 serum IgA titers were
significantly higher in Aboriginal children with OM than in healthy controls (P  0.001)
(Fig. 1B). Anti-P4 and anti-PD serum IgA titers were similar among the groups.
Salivary antibody titers to all 3 NTHi proteins in Aboriginal children with OM
were similar to or higher than those in non-Aboriginal children with OM and
healthy controls. Anti-P4 salivary IgA titers were significantly higher in Aboriginal
children with OM (P  0.050), but not non-Aboriginal children with OM, than in healthy
controls (Fig. 1D). Both anti-P6 IgA and IgG titers were significantly higher in Aboriginal
children with OM than in non-Aboriginal children with OM (P  0.050 and P  0.002,
respectively) (Fig. 1C and D). There were no significant differences in anti-PD salivary
IgG (Fig. 1C) or IgA (Fig. 1D) titers for any of the proteins between the groups; however,
salivary anti-PD antibody titers tended to be higher in Aboriginal children with OM than
in healthy controls.
The numbers of children who did not produce any detectable antigen-specific
antibodies (i.e., nonresponders) were assessed among the groups. All children had
detectable levels of serum IgG and IgA for all 3 NTHi proteins, while non-Aboriginal
children with OM had more saliva samples below the limit of detection for anti-P6 IgA
and IgG than did Aboriginal children with OM (P  0.027 and P  0.003, respectively).
Healthy control children had more saliva samples below the limit of detection for
anti-PD IgG than did non-Aboriginal children with OM (P  0.017). No other differences
in the numbers of nonresponders were observed between the groups.
Antibody production in response to NTHi protein antigens occurs both muco-
sally and systemically. Ratios of IgA to IgG antibody levels were compared for serum
and saliva specimens, to determine whether antibodies in the saliva samples were
mucosally produced or were present due to serum transudation. Highly significant
differences (P  0.006) in the IgA/IgG ratios in serum and saliva samples were observed
for antibodies to all 3 NTHi proteins, suggesting that IgG and IgA antibodies to these
proteins are produced both systemically and mucosally. Spearman rho correlations
were performed between serum and salivary IgA levels and serum and salivary IgG
levels. Antibodies to all proteins had weak to moderate positive correlations (r  0.221
to 0.465; P  0.009) for the entire cohort, in keeping with differential production at the
mucosal and systemic levels.
NTHi-antigen-specific antibody development during childhood differed be-
tween the populations, with a tendency to decrease with age in otitis-prone
Aboriginal children. Antigen-specific IgA and IgG production was correlated with the
age of each child, to assess antibody development during childhood in the different
groups (Tables 2 and 3). For healthy control children, moderate positive correlations
TABLE 2 Correlations of serum IgA and IgG levels with agea
Antigen and group






Healthy controls 0.205 0.25 0.008 0.97
Non-Aboriginal children with OM 0.111 0.35 0.128 0.28
Aboriginal children with OM 0.169 0.17 0.231 0.06
P6
Healthy controls 0.544 0.01 0.039 0.83
Non-Aboriginal children with OM 0.014 0.91 0.112 0.35
Aboriginal children with OM 0.127 0.30 0.171 0.16
PD
Healthy controls 0.469 0.01 0.419 0.01
Non-Aboriginal children with OM 0.174 0.14 0.025 0.84
Aboriginal children with OM 0.183 0.13 0.346 0.01
aWeak correlations were defined as r  0.3 to 0.1 or r  0.1 to 0.3, moderate correlations as r  0.5 to
0.3 or r  0.3 to 0.5, and strong correlations as r  1.0 to 0.5 or r  0.5 to 1.0.
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between age and anti-P6 serum IgA titers (r  0.544; P  0.001), anti-PD serum IgA
titers (r  0.469; P  0.005), and anti-PD serum IgG titers (r  0.419; P  0.014) were
observed (Table 2). Weak positive correlations between age and anti-P6 salivary IgA
titers (r  0.393; P  0.018) were also observed for healthy control children (Table 3).
For non-Aboriginal children with OM, moderate positive correlations between age and
anti-P6 salivary IgA titers (r  0.582; P  0.001) and anti-PD salivary IgA titers (r  0.509;
P  0.001) were observed, and a weak positive correlation between age and anti-P4 IgA
titers (r  0.267; P  0.045) was observed (Table 3). For Aboriginal children with OM,
the only significant correlation between antibody titers and age that was observed was
a weak negative correlation for anti-PD serum IgG titers (r  0.346; P  0.004) (Table
2). Anti-P4 and anti-P6 serum IgG titers were also negatively correlated with age for
Aboriginal children with OM (Table 2); although those correlations did not reach
significance, the findings do indicate that NTHi serum IgG titers do not appear to
increase with age in Aboriginal children with OM.
DISCUSSION
Our data indicated that Australian Aboriginal children undergoing surgery for
chronic or recurrent OM had impaired antigen-specific serum IgG antibody responses
to NTHi antigens. This was particularly evident for PD, the carrier protein in PHiD10-CV,
which is currently being assessed for its impact on OM in Australian Aboriginal
children (the PREVIX-COMBO trial, registered at ClinicalTrials.gov under registration no.
NCT01174849). Specifically, our data showed that Aboriginal children had approxi-
mately 25% of the serum IgG antibody responses to PD seen with healthy non-
Aboriginal children, suggesting that either hyporesponsiveness or the development of
immune tolerance to PD may occur in this high-risk population. This may contribute to
the higher rates of NTHi infection and more severe disease observed in these children
and has implications for vaccination with PHiD10-CV. These results do suggest that,
when protection from NTHI OM is observed among PHiD10-CV-vaccinated children, it
may not be only secondary to pneumococcal protection (33) but may be due to the
development or boosting of anti-PD antibodies. Previous studies by our group did not
identify aberrant immune responses to NTHi proteins in young non-Aboriginal children
with rAOM (14); however, others demonstrated that otitis-prone children have poor
responses to NTHi proteins following AOM (23, 25). NTHi-specific antibody deficiencies
have also been described for adults with chronic obstructive pulmonary disease
(COPD), diabetes mellitus, and chronic renal failure, who experience high rates of NTHi
infection, compared to age-matched healthy controls (45). Antibody deficiency was
particularly evident in adults with COPD, with 63% of patients having no detectable
TABLE 3 Correlations of salivary IgA and IgG levels with agea
Antigen and group






Healthy controls 0.287 0.09 0.139 0.42
Non-Aboriginal children with OM 0.267 0.04 0.007 0.96
Aboriginal children with OM 0.086 0.55 0.058 0.69
P6
Healthy controls 0.393 0.02 0.073 0.67
Non-Aboriginal children with OM 0.582 0.01 0.195 0.15
Aboriginal children with OM 0.082 0.57 0.029 0.84
PD
Healthy controls 0.279 0.10 0.110 0.52
Non-Aboriginal children with OM 0.509 0.01 0.037 0.78
Aboriginal children with OM 0.132 0.36 0.126 0.38
aWeak correlations were defined as r  0.3 to 0.1 or r  0.1 to 0.3, moderate correlations as r  0.5 to
0.3 or r  0.3 to 0.5, and strong correlations as r  1.0 to 0.5 or r  0.5 to 1.0.
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anti-PD serum IgG (45). These data suggest that populations at high risk of NTHi
infection have impaired responses to NTHi antigens, particularly PD. A study by Pizzutto
et al. demonstrated that both healthy children and children affected by chronic
suppurative lung disease (CSLD), to whom Australian Aboriginal children dispropor-
tionately contribute, responded well to vaccination with PHiD-CV10; however, suba-
nalyses of initial titers for healthy versus CSLD-affected children and Aboriginal versus
non-Aboriginal children were not conducted (46). Our data suggest that these are
important analyses to conduct and understand if we are to know what benefits
PHiD-CV10 may elicit. Previous studies in which protection from NTHi-caused AOM by
PHiD10-CV was not demonstrated (28–30) were conducted in populations with much
lower rates of NTHi carriage, AOM, and NTHi-caused AOM, compared to high-risk
indigenous populations such as Australian Aboriginal children (13). Furthermore, there
are no data on antigen-specific antibody titers to PD in low-risk PHiD10-CV-vaccinated
populations, to determine whether immunological deficiencies exist in these children
that may be boosted by using the PHiD10-CV vaccine. Specific studies to determine
whether PHiD10-CV immunization boosts anti-PD antibody titers in these high-risk
populations and whether this contributes to protection from NTHi disease, as observed
for OM in Aboriginal children immunized with PHiD10-CV (26), are warranted.
A recent study assessed the ontogeny of antibody responses to P6 and PD in
children from birth to 6 years of age (47). The data indicated that children below the
age of 1 month had the lowest antibody titers against P6 and PD; titers increased at 1
to 6 months, peaked at 7 months to 3 years, and then remained high at 4 to 6 years (47).
Interestingly, in our study of children between 1 and 15 years of age, while an increase
in PD IgG antibody titers with age was observed for healthy control children (Table 2),
no increase was observed for P6 (or P4). No significant increases in antibody titers with
age were observed for non-Aboriginal children with OM, and negative correlations
between age and antibody titers for all proteins were observed for Aboriginal children,
although the correlation was significant only for PD. This negative correlation suggests
that there may be development of tolerance to these vaccine antigens that could affect
both the initial susceptibility to disease and the implementation of vaccines in this
population. A limitation to our study is that we did not collect nasopharyngeal swabs
and therefore cannot comment on correlations between NTHi colonization and anti-PD
antibody titers.
Among children, naturally acquired serum antibodies to PD are thought to be
acquired in the first 2 to 3 years of life and appear to be bactericidal (22, 23, 48). High
anti-PD IgG titers do not always correlate with neutralizing activity (49), however, and
the functionality of the antibodies measured, rather than just titers alone, is likely to be
important. A Finnish vaccination study suggested that it was the inhibitory function of
the anti-PD antibodies, rather than titers, that was predictive of protection against OM
(49); however, the enzymatic assay used has not been able to be reproduced by us or
other groups.
Our study also showed that Australian Aboriginal children with OM had lower
anti-P6 and anti-P4 serum IgG titers than did non-Aboriginal children with OM and
healthy controls, despite having the same or higher serum IgA and salivary IgA and IgG
titers to all proteins measured. These data suggest that serum IgG antibodies may be
important in preventing OM or in promoting clearance of the underlying infection.
Studies in animal models (rats, mice, and chinchillas) have shown that intranasal and
subcutaneous vaccination with P6 and/or P4 elicits production of bactericidal antibod-
ies that provide protection against the development of NTHi AOM and enhance
mucosal clearance (38–42). Data for anti-P4 and anti-P6 antibodies in otitis-prone
children are as conflicting as those for anti-PD antibodies (14, 23, 25), further suggest-
ing that population-specific responses to NTHi need to be understood to enable
development of an effective NTHi vaccine with broad global application, particularly for
high-risk populations.
Our data indicate that poor serum IgG responses to NTHi proteins may contribute
to the increased risk of severe or chronic OM observed in Australian Aboriginal children.
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This is important for understanding the potential benefits of PHiD10-CV implementa-
tion for indigenous populations and the ability of such children to respond to other
potential NTHi vaccine candidates (i.e., P4 and P6). Whether vaccination with an NTHi
protein, such as PD in PHiD10-CV, in infancy can boost antigen-specific antibody
responses in Aboriginal Australian children and reduce the risk of developing OM has
yet to be determined but is the subject of an ongoing clinical trial. Investigation into
the causality of impaired NTHi protein responses in populations with high rates of NTHi
exposure will contribute to our understanding of immune tolerance, which is essential
for developing vaccines for these high-risk populations.
MATERIALS AND METHODS
Otitis media cases. Children between 0 and 15 years of age were recruited at the time of admission
for tympanoplasty or ventilation tube insertion, through public hospitals in urban and remote Western
Australian hospitals (in Perth, Broome, and Derby), in 2003 to 2008. Written informed consent was
obtained from the parents or guardians. Clinical data were collected using parental questionnaires and
medical records.
Children were included if they met clinical criteria to undergo ventilation tube insertion for either
OME or rAOM or tympanoplasty for CSOM. The diagnosis was recorded at the time of surgery. OME was
defined as the presence of MEE, without symptoms or signs of suppurative infection (50), for longer than 3
months. rAOM was clinically defined, based on diagnoses by primary physicians and otorhinolaryngologists,
as at least 3 AOM presentations within a 6-month period or 4 presentations within a 12-month period,
between which clinical symptoms resolved (50). CSOM was defined as persistent discharge from the middle
ear for more than 6 weeks through a perforation of the tympanic membrane (50); however, otorrhea was
resolved prior to tympanoplasty. Approval for this study was obtained from the Princess Margaret Hospital for
Children (ethics approval number 831EP), Armadale-Kelmscott Memorial Hospital, and Osborne Park Hospital
ethics committees, the Western Australian Aboriginal Health Ethics Committee, and Aboriginal community-
controlled health services in the Kimberley and Eastern Goldfields regions.
Healthy controls. Children between 2 and 15 years of age were recruited through the Vaccine Trials
Group at the Princess Margaret Hospital for Children (Perth, Western Australia, Australia) between 2007 and
2009. Children were eligible if they were healthy and had no history of recurrent or chronic OM, no previous
ear, nose, or throat surgery, no history of an obstructive sleep disorder, no history of chronic or recurrent
sinusitis or rhinitis, and no history of pneumonia or chronic lung disease. Written informed consent was
obtained from the parents or guardians. Clinical data were collected using parental questionnaires. Approval
for this study was obtained from the Princess Margaret Hospital for Children ethics committee (ethics approval
number 1385EP). Exclusion criteria for both cohorts included any chromosomal or craniofacial disorders,
known immunodeficiency, or receipt of immunosuppressive therapy.
Sample collection. General anesthesia was used during the surgical procedures and, utilizing an
operating microscope, an anteroinferior myringotomy incision was made. If MEE was present, then this
was collected utilizing a 2-ml syringe with a blunt drawing-up needle. MEE samples were transported on
ice within 4 h to the PathWest clinical microbiology laboratory at the Princess Margaret Hospital for
Children, for bacteriological culture using standard culture techniques (20). Serum and saliva specimens
were collected as described previously (20).
Measurement of levels of IgG and IgA against NTHi proteins P4, P6, and PD. The H. influenzae
proteins P4 and P6 were expressed and purified as described previously (14); recombinant PD was
provided by Wayne Thomas and Belinda Hales (46). Antibody titers were measured as described
previously, using an in-house multiplex bead-based assay (14).
Total protein assay. To standardize salivary antibody levels across the cohort, total protein levels
were measured using the Micro BCA (bicinchoninic acid) protein assay kit (Thermo Scientific), following
the manufacturer’s instructions, as described previously (20). Saliva antibody titers were standardized as
arbitrary units (AU) per milligrams of total protein in the saliva (14).
Statistical analyses. Host and environmental risk factors were compared between Aboriginal and
non-Aboriginal children with OM and healthy control children using Student’s t tests for continuous
variables (age) and Pearson’s chi-square analyses (asymptotic significant 2-sided P values) for categorical
variables (gender and day care attendance). Differences in frequencies of diagnoses and surgery,
numbers of children in each age category, and numbers of samples below the assay detection limit for
Aboriginal children versus non-Aboriginal children were assessed using chi-square analyses. Serum
antibody titers were expressed as AU per milliliter against a reference human serum pool and are
reported as adjusted antigen-specific geometric mean concentrations (GMCs), with 95% confidence
intervals (CIs), correcting for age as a confounding variable. Adjusted GMCs were calculated by using
logarithmically transformed, adjusted antibody concentrations. Salivary antibody titers were calculated
as for serum titers and then were adjusted, to correct for interpatient variations in saliva production, by
correcting the results to 1 mg/ml of total protein in the sample. Univariate analyses, using a general linear
regression model and adjusting for age, were used to assess differences in anti-NTHi antibody levels
between Aboriginal and non-Aboriginal children with OM and healthy control children. Paired-sample t
tests were used to determine differences in IgA/IgG ratios in serum and saliva samples. The IBM SPSS
Statistics 20 for Windows software package (IBM, Armonk, NY, USA) was used for all statistical analyses,
and data were plotted using GraphPad Prism 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
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